Pharmaceuticals
United
States
Biopharmaceutical
Rare
Treatments
Commercializing
M&A Advisory
Lazard
Full Credential Description
Savient Pharmaceuticals. United States. Announced Date 07/10/2009. Closed Date 15/10/2009. Deal value: $57m. Common stock. Industry: Savient Pharmaceuticals was a biopharmaceutical company focused on developing and commercializing treatments for rare diseases.